Literature DB >> 31960910

Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.

Jonasz J Weber1,2,3, Eva Haas1,2, Yacine Maringer1,2, Stefan Hauser4, Nicolas L P Casadei1,2, Athar H Chishti5, Olaf Riess1,2, Jeannette Hübener-Schmid1,2.   

Abstract

Proteolytic fragmentation of polyglutamine-expanded ataxin-3 is a concomitant and modifier of the molecular pathogenesis of Machado-Joseph disease (MJD), the most common autosomal dominant cerebellar ataxia. Calpains, a group of calcium-dependent cysteine proteases, are important mediators of ataxin-3 cleavage and implicated in multiple neurodegenerative conditions. Pharmacologic and genetic approaches lowering calpain activity showed beneficial effects on molecular and behavioural disease characteristics in MJD model organisms. However, specifically targeting one of the calpain isoforms by genetic means has not yet been evaluated as a potential therapeutic strategy. In our study, we tested whether calpains are overactivated in the MJD context and if reduction or ablation of calpain-1 expression ameliorates the disease-associated phenotype in MJD cells and mice. In all analysed MJD models, we detected an elevated calpain activity at baseline. Lowering or removal of calpain-1 in cells or mice counteracted calpain system overactivation and led to reduced cleavage of ataxin-3 without affecting its aggregation. Moreover, calpain-1 knockout in YAC84Q mice alleviated excessive fragmentation of important synaptic proteins. Despite worsening some motor characteristics, YAC84Q mice showed a rescue of body weight loss and extended survival upon calpain-1 knockout. Together, our findings emphasize the general potential of calpains as a therapeutic target in MJD and other neurodegenerative diseases.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31960910      PMCID: PMC7158375          DOI: 10.1093/hmg/ddaa010

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  61 in total

1.  Calpastatin is up-regulated in response to hypoxia and is a suicide substrate to calpain after neonatal cerebral hypoxia-ischemia.

Authors:  K Blomgren; U Hallin; A L Andersson; M Puka-Sundvall; B A Bahr; A McRae; T C Saido; S Kawashima; H Hagberg
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

Review 2.  Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells.

Authors:  A Czogalla; A F Sikorski
Journal:  Cell Mol Life Sci       Date:  2005-09       Impact factor: 9.261

Review 3.  Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease.

Authors:  Austen J Milnerwood; Lynn A Raymond
Journal:  Trends Neurosci       Date:  2010-09-17       Impact factor: 13.837

4.  Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease.

Authors:  Ana Teresa Simões; Nélio Gonçalves; Rui Jorge Nobre; Carlos Bandeira Duarte; Luís Pereira de Almeida
Journal:  Hum Mol Genet       Date:  2014-05-09       Impact factor: 6.150

Review 5.  Calpains and neuronal damage in the ischemic brain: The swiss knife in synaptic injury.

Authors:  Michele Curcio; Ivan L Salazar; Miranda Mele; Lorella M T Canzoniero; Carlos B Duarte
Journal:  Prog Neurobiol       Date:  2016-06-06       Impact factor: 11.685

6.  Defects in the CAPN1 Gene Result in Alterations in Cerebellar Development and Cerebellar Ataxia in Mice and Humans.

Authors:  Yubin Wang; Joshua Hersheson; Dulce Lopez; Monia Hammer; Yan Liu; Ka-Hung Lee; Vanessa Pinto; Jeff Seinfeld; Sarah Wiethoff; Jiandong Sun; Rim Amouri; Faycal Hentati; Neema Baudry; Jennifer Tran; Andrew B Singleton; Marie Coutelier; Alexis Brice; Giovanni Stevanin; Alexandra Durr; Xiaoning Bi; Henry Houlden; Michel Baudry
Journal:  Cell Rep       Date:  2016-06-16       Impact factor: 9.423

Review 7.  SNAP-25, a Known Presynaptic Protein with Emerging Postsynaptic Functions.

Authors:  Flavia Antonucci; Irene Corradini; Giuliana Fossati; Romana Tomasoni; Elisabetta Menna; Michela Matteoli
Journal:  Front Synaptic Neurosci       Date:  2016-03-24

8.  The calpain-suppressing effects of olesoxime in Huntington's disease.

Authors:  Jonasz J Weber; Midea M Ortiz Rios; Olaf Riess; Laura E Clemens; Huu P Nguyen
Journal:  Rare Dis       Date:  2016-04-06

9.  Homozygous CAPN1 mutations causing a spastic-ataxia phenotype in 2 families.

Authors:  Cemile Kocoglu; Asli Gundogdu; Gulsen Kocaman; Pinar Kahraman-Koytak; Kayihan Uluc; Gunes Kiziltan; Ahmet Okay Caglayan; Kaya Bilguvar; Atay Vural; A Nazli Basak
Journal:  Neurol Genet       Date:  2018-01-18

10.  Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer's disease brain.

Authors:  Ksenia Kurbatskaya; Emma C Phillips; Cara L Croft; Giacomo Dentoni; Martina M Hughes; Matthew A Wade; Safa Al-Sarraj; Claire Troakes; Michael J O'Neill; Beatriz G Perez-Nievas; Diane P Hanger; Wendy Noble
Journal:  Acta Neuropathol Commun       Date:  2016-03-31       Impact factor: 7.801

View more
  7 in total

1.  Calpain-1 mediates vascular remodelling and fibrosis via HIF-1α in hypoxia-induced pulmonary hypertension.

Authors:  Haiyan Deng; Xiaoxue Tian; Hening Sun; Huan Liu; Meili Lu; Hongxin Wang
Journal:  J Cell Mol Med       Date:  2022-04-01       Impact factor: 5.295

Review 2.  Identifying Therapeutic Targets for Spinocerebellar Ataxia Type 3/Machado-Joseph Disease through Integration of Pathological Biomarkers and Therapeutic Strategies.

Authors:  Yu-Shuan Chen; Zhen-Xiang Hong; Shinn-Zong Lin; Horng-Jyh Harn
Journal:  Int J Mol Sci       Date:  2020-04-26       Impact factor: 5.923

3.  Neurodegenerative phosphoprotein signaling landscape in models of SCA3.

Authors:  Anna S Sowa; Taissia G Popova; Tina Harmuth; Jonasz J Weber; Priscila Pereira Sena; Jana Schmidt; Jeannette Hübener-Schmid; Thorsten Schmidt
Journal:  Mol Brain       Date:  2021-03-19       Impact factor: 4.041

4.  A Novel Calpain Inhibitor Compound Has Protective Effects on a Zebrafish Model of Spinocerebellar Ataxia Type 3.

Authors:  Katherine J Robinson; Kristy Yuan; Stuart K Plenderleith; Maxinne Watchon; Angela S Laird
Journal:  Cells       Date:  2021-09-29       Impact factor: 6.600

Review 5.  Punicic Acid and Its Role in the Prevention of Neurological Disorders: A Review.

Authors:  Claudia M Guerra-Vázquez; Mariana Martínez-Ávila; Daniel Guajardo-Flores; Marilena Antunes-Ricardo
Journal:  Foods       Date:  2022-01-18

6.  Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17.

Authors:  Jonasz Jeremiasz Weber; Stefanie Cari Anger; Priscila Pereira Sena; Rana Dilara Incebacak Eltemur; Chrisovalantou Huridou; Florian Fath; Caspar Gross; Nicolas Casadei; Olaf Riess; Huu Phuc Nguyen
Journal:  Cell Mol Life Sci       Date:  2022-04-28       Impact factor: 9.207

7.  PolyQ-expanded ataxin-3 protein levels in peripheral blood mononuclear cells correlate with clinical parameters in SCA3: a pilot study.

Authors:  Kathrin Gonsior; Gabriele Anna Kaucher; Patrik Pelz; Dorothea Schumann; Melanie Gansel; Sandra Kuhs; Thomas Klockgether; Sylvie Forlani; Alexandra Durr; Stefan Hauser; Tim W Rattay; Matthis Synofzik; Holger Hengel; Ludger Schöls; Olaf H Rieß; Jeannette Hübener-Schmid
Journal:  J Neurol       Date:  2020-10-26       Impact factor: 4.849

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.